Covered — but barely income. The payout is very well covered at a 28.5% earnings payout, and the dividend was raised 1% in May 2026 to $0.5158 a quarter, but at 0.83% the yield is thin income, and the raises are token-sized — this is a safe payer, not a meaningful income holding.
Key risk: Thin-margin drug distribution — pricing pressure from customers and suppliers, plus opioid-settlement obligations, can squeeze the low-margin model even while the payout stays covered.
Changes if: The payout ratio rises sharply on falling earnings, or the annual increase is skipped. Neither is visible now; the yield itself is the standing limitation.
- ✓Payout-coverage check: 28.5% of trailing earnings — $2.06 indicated against earnings implying about $7.22 a share. Covered with a wide margin.
- !Yield check: 0.83% indicated — $0.5158/qtr × 4 at the $249.57 close on Oct. 23, 2026. Real, but thin: $83 a year per $10,000 invested.
- !Dividend growth check: Raised 1% in May 2026, from $0.5107 to $0.5158 a quarter — the increase continues, but at about 1% a year it barely keeps pace.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.